HSCS

HeartSciences Inc. (HSCS) - 10-Q Summary

Business Context and Reporting Period

Company: HeartSciences Inc. (formerly Heart Test Laboratories, Inc.)
Reporting Period: Quarter and nine months ended January 31, 2025 (Fiscal 2025)
Business Model: Medical technology company developing AI-based electrocardiograph (ECG) solutions, specifically the MyoVista wav ECG device and the MyoVista Insights Cloud Platform. The company is pre-revenue in the U.S. market pending FDA clearance.
Recent Corporate Actions: Changed corporate name to HeartSciences Inc. in October 2024; executed a 1-for-100 reverse stock split in May 2024 to regain Nasdaq compliance.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue: No revenue recognized in the current period compared to nominal revenue ($14,700 for 3 months; $18,600 for 9 months) in the prior year, primarily from international distributor relationships.
• Operating Expenses: Total operating expenses increased 54% year-over-year for the quarter ($2.37M vs $1.54M) and 45% for the nine-month period ($6.43M vs $4.44M).
  • R&D: Increased 103% (quarter) and 89% (9 months) due to consulting costs for the Cloud Platform and headcount for FDA submission preparation.
  • SG&A: Increased 30% (quarter) and 14% (9 months), driven by a $611,000 write-off of deferred offering costs from a withdrawn S-1/A registration in December 2024.
• Debt: Notes payable increased significantly from $500,000 to $2.53 million due to the issuance of a $2.51 million unsecured promissory note (Streeterville Note) in September 2024.
• Cash Position: Cash decreased by $3.21 million over the nine-month period, driven by a net cash burn of $5.82 million from operations, partially offset by $2.63 million in financing proceeds.

Guidance, Outlook, Risks, and Unusual Items

• Going Concern: Management has raised substantial doubt regarding the company's ability to continue as a going concern. Current cash resources are deemed insufficient to fund operations for the next 12 months without additional financing.
• Regulatory Outlook: The company is preparing a 510(k) FDA submission for the MyoVista wav ECG device in the first half of 2025. A submission for the Cloud Platform and low ejection fraction algorithm is targeted for the second half of 2025.
• Financing Activities:
  • Streeterville Note: Issued $2.51M note in Sept 2024; net proceeds ~$1.9M. Matures in 18 months with 8.5% interest.
  • Equity Lines: Active Equity Line with Lincoln Park ($15M cap) and ATM Facility with Maxim ($15M cap). Proceeds from these facilities were used to fund operations.
  • Series D Offering: Commenced a "best efforts" offering on March 10, 2025, for up to $15.0 million in Units (Series D Preferred Stock + Warrants). No proceeds received as of the filing date.
• Internal Controls: Disclosure controls and procedures were deemed not effective as of January 31, 2025, due to material weaknesses including lack of proper approval processes, insufficient accounting resources, and inadequate segregation of duties.
• Unusual Items: Write-off of approximately $611,000 in deferred offering costs related to a withdrawn registration statement in December 2024.

Investor Verification Checklist

• Liquidity Runway: Verify the sufficiency of the $2.6M cash balance against the stated burn rate and the timeline for the Series D offering.
• Debt Covenants: Review the terms of the Streeterville Note, specifically the redemption rights, interest rate acceleration upon default, and the requirement to reduce the balance by $900,000 within 12 months.
• FDA Timeline: Monitor the status of the 510(k) submission expected in H1 2025; delays could necessitate further dilutive financing.
• Internal Controls: Assess the remediation plan for the identified material weaknesses in financial reporting controls.
• Equity Dilution: Track the progress of the Series D offering and sales under the Equity Line/ATM facilities, which will significantly increase the share count.